IFNG and leukemia: By contrast, AML patients with a “non-inflamed” or cold TME, or with inherent insensitivity to IFN-γ and other effector molecules, should be offered other immunotherapeutic options, such as the infusion of leukemia antigen-specific T cells and genetically-modified (chimeric antigen receptor) CAR T cells.